Noradrenaline transporter PET reflects neurotoxin-induced noradrenaline level decrease in the rat hippocampus

Area of Science:

• Neuroscience
• Radiochemistry
• Biomarker Development

Background:

• Early Alzheimer's disease (AD) involves noradrenaline neuron loss, impacting cognitive functions and potentially accelerating disease progression.
• Diminished noradrenaline availability is linked to cognitive impairment in AD.
• In vivo biomarkers for noradrenaline neuron integrity are needed to understand the noradrenaline system's role in AD.

Purpose of the Study:

• To investigate if Positron Emission Tomography (PET) imaging of noradrenaline transporters can predict brain noradrenaline levels.
• To test the hypothesis that PET-measured noradrenaline transporter (NET) densities correlate with actual noradrenaline concentrations in the rat hippocampus.

Main Methods:

• Rats underwent chemical lesioning of the hippocampus using DSP-4 to selectively damage noradrenergic neuron terminals.
• PET imaging was performed using [¹¹C]MRB ((S,S)-[¹¹C]Methylreboxetine) to assess noradrenaline transporter densities.
• Postmortem studies measured noradrenaline transporter and noradrenaline concentrations in brain homogenates for validation.

Main Results:

• [¹¹C]MRB PET revealed decreased noradrenaline transporter densities in the hippocampus, dependent on DSP-4 dosage.
• PET-measured noradrenaline transporter densities strongly correlated with in vitro measured noradrenaline concentrations.
• PET-measured transporter densities also correlated well with in vitro transporter densities.

Conclusions:

• [¹¹C]MRB PET can serve as an in vivo biomarker for hippocampal noradrenaline concentrations in neurodegeneration.
• This PET imaging approach shows potential for future application in Alzheimer's disease research.